Intercept Pharmaceuticals Inc (ICPT)

155.94
0.98 0.63
NASDAQ : Health Care
Prev Close 154.96
Open 154.99
Day Low/High 154.50 / 155.80
52 Wk Low/High 89.76 / 217.99
Volume 5.91K
Avg Volume 528.30K
Exchange NASDAQ
Shares Outstanding 24.73M
Market Cap 3.80B
EPS -9.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Insider Trading Alert - ICPT, SPTN And CME Traded By Insiders

Insider Trading Alert - ICPT, SPTN And CME Traded By Insiders

Stocks with insider trader activity include ICPT, SPTN and CME

Intercept Pharmaceuticals Stock Sees Short Interest Make 12.4% Move

Intercept Pharmaceuticals Stock Sees Short Interest Make 12.4% Move

The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 496,919 share increase in total short interest for Intercept Pharmaceuticals Inc , to 4,487,214, an increase of 12.45% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Trade These 5 Biotech Breakouts Now for Big Gains

Trade These 5 Biotech Breakouts Now for Big Gains

Here's a technical look at how to trade five biotech stocks that are setting up to break out and trade much higher.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Barbarian At The Gate: Intercept Pharmaceuticals (ICPT)

Barbarian At The Gate: Intercept Pharmaceuticals (ICPT)

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Intercept Pharmaceuticals (ICPT): Today's Weak On High Volume Stock

Intercept Pharmaceuticals (ICPT): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a weak on high relative volume candidate

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Post-Market Leader Stock

Trade-Ideas: Intercept Pharmaceuticals (ICPT) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a post-market leader candidate

Here's Why Intercept Pharma (ICPT) Stock Is Gaining Today

Here's Why Intercept Pharma (ICPT) Stock Is Gaining Today

Intercept Pharma (ICPT) stock is higher in mid-afternoon trading after the company's treatment for chronic liver disease received accelerated FDA approval.

Heavy Trading On Intercept Pharmaceuticals (ICPT) Before Market Open

Heavy Trading On Intercept Pharmaceuticals (ICPT) Before Market Open

Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a pre-market mover with heavy volume candidate

Investors Eager for Gilead to Make Big Moves

Investors Eager for Gilead to Make Big Moves

Jim Cramer likes Gilead but says investors are waiting for the biopharmaceutical company to make a more transformative move.

Gilead (GILD) Shares Spike After Executive Board Appointment

Gilead (GILD) Shares Spike After Executive Board Appointment

Analysts say the drugmaker is a good investment for short-term buyers or those who bet on risk.

Biotech Is Ripe for M&A: Analysts

After an asset price drop, large pharmaceutical companies are looking for strategic purchases.

Insider Trading Alert - ACTG, RNR And ICPT Traded By Insiders

Insider Trading Alert - ACTG, RNR And ICPT Traded By Insiders

Stocks with insider trader activity include ACTG, RNR and ICPT

Intercept Pharma (ICPT) Stock Slips, Downgraded at Morgan Stanley

Intercept Pharma (ICPT) Stock Slips, Downgraded at Morgan Stanley

Intercept Pharma (ICPT) stock is falling on Friday afternoon as Morgan Stanley downgraded the company to ‘underweight.’

Intercept Seen As Takeover Target, But Morgan Stanley Says Sell

Intercept Seen As Takeover Target, But Morgan Stanley Says Sell

Yesterday, an FDA advisory committee voted unanimously to recommend approval of Intercept Pharmaceuticals' Ocaliva, which sparked positive comments from several analysts.